Jiajv Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jiajv Chen has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Wei Li
School of Law, Jinan University
5 shared publications Hanyang Zhang
Institute of Intellectual Property, University of Science and Technology of China, Hefei 230022, China
1 shared publicationShuren Tao
Institute of Intellectual Property, University of Science and Technology of China, Hefei, Anhui, China
1 shared publicationWei Zhang
School of Law, Zhejiang Gongshang University, Hangzhou 310018, China
1 shared publicationXuekai Xie
School of Law, East China University of Science and Technology, 130 Meilong Road, Xuhui District, Shanghai, China
1 shared publication- Yichao Chen
Law School & Intellectual Property School, Jinan University, Guangzhou, Guangdong, China
1 shared publication
Latest Publications
- 9 June 2025
- Published by Springer Nature in Human Genetics
- Vol. 144 (7) , 715-725
Is cross-border transfer of China’s human genetic data an impossible mission?
Cross-border transfer of human genetic data is a crucial prerequisite for sharing such data globally. However, given the unique nature of human genetic data, this aspiration may not be easily realized. China, a country rich in biological resources, possesses a vast wealth of human genetic data. However, due to China’s domestic laws and policies, human genetic data is considered both personal information, subject to regulations like the Personal Information Protection Law, and human genetic resources, governed by the Regulations on Management of Human Genetic Resources. This dual nature necessitates a double security review of human genetic data for cross-border transfer, rendering cross-border transfer of China’s human genetic data a seemingly impossible mission. However, in recent years, China has refined its security review rules for cross-border data transfer to increase transparency and, in practice, has eased review criteria, issuing numerous administrative licenses. Such a shift of stance is not fortuitous but rather a planned and purposeful reflection of China’s top-level design to promote self-reliance and self-improvement in science and technology, as well as its strategic goal of joining international digital economy organizations.
- 9 June 2025
- Published by Springer Nature in Human Genetics
- Vol. 144 (7) , 715-725
Is cross-border transfer of China’s human genetic data an impossible mission?
Cross-border transfer of human genetic data is a crucial prerequisite for sharing such data globally. However, given the unique nature of human genetic data, this aspiration may not be easily realized. China, a country rich in biological resources, possesses a vast wealth of human genetic data. However, due to China’s domestic laws and policies, human genetic data is considered both personal information, subject to regulations like the Personal Information Protection Law, and human genetic resources, governed by the Regulations on Management of Human Genetic Resources. This dual nature necessitates a double security review of human genetic data for cross-border transfer, rendering cross-border transfer of China’s human genetic data a seemingly impossible mission. However, in recent years, China has refined its security review rules for cross-border data transfer to increase transparency and, in practice, has eased review criteria, issuing numerous administrative licenses. Such a shift of stance is not fortuitous but rather a planned and purposeful reflection of China’s top-level design to promote self-reliance and self-improvement in science and technology, as well as its strategic goal of joining international digital economy organizations.
- 16 August 2024
- Published by SAGE Publications in Human Gene Therapy
- Vol. 35 (15-16) , 520-526
The Legal Status and Improvement Path of Human Genetic Data in Gene Therapy in China
In the legal context of Chinese law, genetic data are an object of complex rights. At the level of private law, genetic data contain personal information, thus being protected by the Civil Code and the Personal Information Protection Law. At the level of public law, genetic data are important genetic resource that embody both public and national interests, which should also be regulated by public laws such as the Biosecurity Law and the Data Security Law. The recently issued Regulation on the Administration of Human Genetic Resources have refined the approval and record procedure, in order to promote the utilization of genetic data in China. At present, China still lacks sufficient protection for genetic data privacy, and the “informed consent” and “anonymization” system cannot work effectively. On the path of improvement, we should break constraints of individualism and start from the following three levels to strengthen genetic data privacy protection: formulating specialized legislation and leveraging the functions of group organizations and public interest litigation systems.
- 16 August 2024
- Published by SAGE Publications in Human Gene Therapy
- Vol. 35 (15-16) , 520-526
The Legal Status and Improvement Path of Human Genetic Data in Gene Therapy in China
In the legal context of Chinese law, genetic data are an object of complex rights. At the level of private law, genetic data contain personal information, thus being protected by the Civil Code and the Personal Information Protection Law. At the level of public law, genetic data are important genetic resource that embody both public and national interests, which should also be regulated by public laws such as the Biosecurity Law and the Data Security Law. The recently issued Regulation on the Administration of Human Genetic Resources have refined the approval and record procedure, in order to promote the utilization of genetic data in China. At present, China still lacks sufficient protection for genetic data privacy, and the “informed consent” and “anonymization” system cannot work effectively. On the path of improvement, we should break constraints of individualism and start from the following three levels to strengthen genetic data privacy protection: formulating specialized legislation and leveraging the functions of group organizations and public interest litigation systems.
- Open Access
- 21 September 2023
- Published by Elsevier in Stem Cell Reports
- Vol. 18 (10) , 1899-1904
How to promote the accessibility of technology in the era of hESC patents—A comparative analysis of the systems of the US and China
- 21 September 2023
- Published by Elsevier in Stem Cell Reports
- Vol. 18 (10) , 1899-1904
Open AccessHow to promote the accessibility of technology in the era of hESC patents—A comparative analysis of the systems of the US and China
- 14 November 2022
- Published by SAGE Publications in Human Gene Therapy
- Vol. 33 (21-22) , 1121-1125
After He Jiankui's Case: Chinese Legislative Modifications in Human Embryo Gene Editing
This article systematically discusses Chinese current legal status and rules for human embryo gene editing in both administrative law and criminal law after several legislative modifications, and further systematically evaluates the values and the defects of these modifications. After He Jiankui's case, Chinese legislators devoted themselves to improve human embryo gene editing legislation. As a result, human embryo gene editing's legal status becomes more determined. Rules for human embryo gene editing in Chinese administrative law have gradually become a complete system centering on “ CBL-regulation ,” and the promulgation of Amendment (XI) to the Criminal Law reconciles the controversy existed in academic circles. Chinese rules for human embryo gene editing are moving from “doubtful development” to “complete legal system.”
- 14 November 2022
- Published by SAGE Publications in Human Gene Therapy
- Vol. 33 (21-22) , 1121-1125
After He Jiankui's Case: Chinese Legislative Modifications in Human Embryo Gene Editing
This article systematically discusses Chinese current legal status and rules for human embryo gene editing in both administrative law and criminal law after several legislative modifications, and further systematically evaluates the values and the defects of these modifications. After He Jiankui's case, Chinese legislators devoted themselves to improve human embryo gene editing legislation. As a result, human embryo gene editing's legal status becomes more determined. Rules for human embryo gene editing in Chinese administrative law have gradually become a complete system centering on “ CBL-regulation ,” and the promulgation of Amendment (XI) to the Criminal Law reconciles the controversy existed in academic circles. Chinese rules for human embryo gene editing are moving from “doubtful development” to “complete legal system.”
- 16 December 2021
- Published by SAGE Publications in Human Gene Therapy
- Vol. 32 (23-24) , 1495-1500
Institutional Framework for the Management of Human Genetic Resources in China
China has made efforts toward the preservation and utilization of human genetic resources (HGRs). In recent years, in the face of various issues that have become increasingly prominent in HGR research, China has continuously strengthened legislation and ethics, and has initially established a relatively complete legal system and ethical guidelines. In the design of regulatory responsibilities, a multisectoral linkage of the Ministry of Science and Technology (MOST), the National Health Commission (NHC), the National Medical Products Administration (NMPA), and the National Intellectual Property Administration (CNIPA) has been formed. In the supervision system, it includes a three-tier structure of Laws/Acts-Regulations-Guidance. In terms of management content, it mainly draws on the basic principles of international conventions such as the Convention on Biological Diversity (CBD), and implements examination and approval filing management and ethical supervision of HGR research in China.
- 16 December 2021
- Published by SAGE Publications in Human Gene Therapy
- Vol. 32 (23-24) , 1495-1500
Institutional Framework for the Management of Human Genetic Resources in China
China has made efforts toward the preservation and utilization of human genetic resources (HGRs). In recent years, in the face of various issues that have become increasingly prominent in HGR research, China has continuously strengthened legislation and ethics, and has initially established a relatively complete legal system and ethical guidelines. In the design of regulatory responsibilities, a multisectoral linkage of the Ministry of Science and Technology (MOST), the National Health Commission (NHC), the National Medical Products Administration (NMPA), and the National Intellectual Property Administration (CNIPA) has been formed. In the supervision system, it includes a three-tier structure of Laws/Acts-Regulations-Guidance. In terms of management content, it mainly draws on the basic principles of international conventions such as the Convention on Biological Diversity (CBD), and implements examination and approval filing management and ethical supervision of HGR research in China.
- Open Access
- 25 November 2020
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 11 (1) , 1-8
From strict moral standards to ethical neutrality: a policy-guided shift in the patentability of human embryonic stem cells in China
Attitudes towards human embryonic stem cells (hESCs) in China have witnessed a significant shift in 2020 that can be attributed to China’s policy guidance. For ethical reasons, stricter standards are adopted to curb related regulations and patent licensing. Through the introduction of policies, some research on hESCs has been recognized as legitimate and feasible to a certain standard and scope. In the subsequent practice of patent examination, the dual influence of policy support and public interest has led to a shift in the examination standards of China’s intellectual property authority from “strict morality” to “ethical neutrality”, implying limited recognition of hESCs’ patentability. In view of the promotion of policy incentives for the transformation and application of corresponding research, there is considerable social demand to provide patent protection for research results. In this context, an adjustment of related regulations is illustrated in this revision, manifesting a partial shift in regulations towards a supportive stance consistent with policy.
- 25 November 2020
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 11 (1) , 1-8
Open AccessFrom strict moral standards to ethical neutrality: a policy-guided shift in the patentability of human embryonic stem cells in China
Attitudes towards human embryonic stem cells (hESCs) in China have witnessed a significant shift in 2020 that can be attributed to China’s policy guidance. For ethical reasons, stricter standards are adopted to curb related regulations and patent licensing. Through the introduction of policies, some research on hESCs has been recognized as legitimate and feasible to a certain standard and scope. In the subsequent practice of patent examination, the dual influence of policy support and public interest has led to a shift in the examination standards of China’s intellectual property authority from “strict morality” to “ethical neutrality”, implying limited recognition of hESCs’ patentability. In view of the promotion of policy incentives for the transformation and application of corresponding research, there is considerable social demand to provide patent protection for research results. In this context, an adjustment of related regulations is illustrated in this revision, manifesting a partial shift in regulations towards a supportive stance consistent with policy.